Showing results (321-330 of 351) with videos related to

Sort By:
Pageof 36
The Lancet. Infectious Diseases|June 1, 2022
Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance dataMichael W Traeger, Rebecca Guy, Jason Asselin, et al.
The Lancet Regional Health. Western Pacific|September 12, 2024
Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022Michael W Traeger, Rebecca Guy, Caroline Taunton, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
AIDS and Behavior|December 21, 2017
Understanding the Targeting and Uptake of HIV Testing Among Gay and Bisexual Men Attending Sexual Health ClinicsMuhammad S Jamil, Hamish McManus, Denton Callander, et al.
Emerging Infectious Diseases|August 19, 2017
Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, AustraliaDavid M Whiley, Ella Trembizki, Cameron Buckley, et al.
BMC Infectious Diseases|February 3, 2011
'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women'Jennifer Walker, Christopher K Fairley, Catriona S Bradshaw, et al.
Sexual Health|February 19, 2024
Chlamydia retesting remains low among young women in Australia: an observational study using sentinel surveillance data, 2018-2022Stephanie C Munari, Anna L Wilkinson, Jason Asselin, et al.
Plos One|June 5, 2012
Chlamydia trachomatis incidence and re-infection among young women--behavioural and microbiological characteristicsJennifer Walker, Sepehr N Tabrizi, Christopher K Fairley, et al.
Plos Medicine|November 8, 2017
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational studyMark A Boyd, Amanda Mocroft, Lene Ryom, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Pageof 36